Generic group Gna, b

2012 ◽  
Author(s):  
Chillali Abdelhakim
Keyword(s):  
Generic Group

scholarly journals Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4156-4156
Author(s):  
Ekin Kircali ◽  
Guldane Cengiz Seval ◽  
Sinem Civriz Bozdag ◽  
Selami Kocak Toprak ◽  
Meltem Kurt Yuksel ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Research Funding ◽  
Chronic Phase ◽  
Response Rates ◽  
Molecular Response ◽  
Optimal Response ◽  
Generic Group ◽  
Significant Difference ◽  
Generic Groups ◽  
Support Research

Introduction:Generic imatinib formulations are increasingly being used as more affordable alternatives worldwide and a few studies have evaluated the safety and efficacy of these formulations prospectively. We have retrospectively analyzed our CML cohort in terms of first line treatment of Glivec versus generic imatinib. This study aims to evaluate the safety and efficacy of generic imatinib products in chronic phase chronic myeloid leukemia as first line treatment. Methods:We have retrospectively analyzed our CML cohort from January 2000 to December 2018 treated with either Glivec or one of generic imatinib formulations. All of our patients (with 1 exception) were initiated imatinib in chronic phase in less than 56 days from diagnosis. All of our patients were followed in accordance with European Leukemia Net (ELN) 2013 recommendations and national hematology association CML guidelines and response definitions were applied according to ELN 2013 criteria. Event free survival (EFS) was defined as the time between treatment initiation and either loss of hematological response, progression to accelerated phase (AP) or blastic phase (BP), or death from any cause. Progression free survival was defined as the time between treatment initiation and transformation to AP, BP or death while on imatinib. For statistical analyses SPSS version 21.0 was used. All p values < 0.05 were considered statistically significant. Results:A total of 192 patients were analyzed comparing 102 (53.1 %) patients on Glivec with 90 patients on (476.9 %) generic formulations. 99 (51.6 %) were female patients. The median age of our population was median 46 years (14-88 years) for Glivec and median 51 years (19-79 years) for generic group (p=0.01). Risk stratifications according to Sokal, Hasford and ELTS scores were run for both Glivec and generic formulation groups. Most of the patients had low risk according to Sokal (137, 71.4%) and Hasford (116, 60.4 %) but intermediate risk according to ELTS (113, 58.9 %) scoring systems. There was no statistically significant difference in the gender distribution, Sokal, Hasford, ELTS scores and ECOG between the two groups. The median time to initiate imatinib treatment was 23.5 (1- 156) days for Glivec group and 13 (1- 51) days generic group (p< 0.05). But the late onset of the treatment was not associated with treatment failure or death. The median follow up was 119.8 (3.7- 250.5) months for Glivec group and 43.6 (2- 150) months for generic groups, respectively (p< 0.05). This difference might be explained by the fact that Glivec has been on the market for about two decades. Similar rates of grade> 2 hematological and non- hematological toxicity were seen in Glivec (4.9 %) and generic groups (3.3 %), respectively (p> 0.05). The rates of treatment failure at 3 months were significantly higher in generic formulation (6.7 %) group than Glivec (2.9 %) group (p< 0.05). Also, the rates of treatment failure at 6 months were significantly higher in generic formulation (3.3 %) group than Glivec (0.9 %) group (p< 0.05). Optimal molecular response rate at 3 months was 76.5 % (n=78) for Glivec and 32.2 % (n=29) for generic groups (p< 0.001). Also, optimal molecular response rate at 6 months was 69.6 % (n=71) for Glivec and 45.6 % (n=41) for generic groups (p= 0.01). Median EFS was found significantly higher for Glivec group compared to generic group (168 mos (95% CI: 159-177 mos) vs 74.6 mos (95% CI: 56-93); p<0.001) (Figure). Conclusion: We found that complete hematological response rates at 3 and 6 months were similar in both groups, but in early phase of treatment the optimal response rates of Glivec group was statistical significantly higher than generic group. Generic group presented with a lower rate of optimal response at 3 months but 13.4 % improvement in optimal response rates was observed at six months. No significant difference in safety concerns was observed between the groups. We recommend that these results from single center should be clarified in a prospective, randomized study including larger population. Figure Disclosures Özcan: AbbVie: Other: Travel support, Research Funding; MSD: Research Funding; Novartis: Research Funding; Amgen: Honoraria, Other: Travel support; BMS: Other: Travel support; Jazz: Other: Travel support; Sanofi: Other: Travel support; Abdi Ibrahim: Other: Travel support; Janssen: Other: Travel support, Research Funding; Bayer: Research Funding; Celgene Corporation: Research Funding, Travel support; Takeda: Honoraria, Other: Travel support, Research Funding; Archigen: Research Funding; Roche: Other: Travel support, Research Funding. Beksac:Celgene: Speakers Bureau; Janssen: Research Funding, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Psychiatric Disorders and Reactions: Definitions and Manner of Recording

1946 ◽  
Vol 92 (387) ◽  
pp. 425-441
Keyword(s):  
Psychiatric Disorders ◽  
Specific Reaction ◽  
Generic Group ◽  
General Plan ◽  
Psychiatric Conditions ◽  
Specific Reactions

In setting up the definitions of psychiatric conditions, the term “disorder” has been used for the designation of the generic group of the specific reactions, while the specific reaction types have been termed “reactions.” In classifying psychoneuroses, the dynamics of the psychopathology was chosen as the basis. Of necessity, a few terms remained descriptive (symptomatic). In general, an attempt has been made to retain only such formerly used terms as could be fitted into this general plan and omit categories which are “catch-alls,” such as “Simple adult maladjustment,” “Constitutional psychopathic state,” etc.

On the multiplicity function of generic group extensions with continuous spectrum

2001 ◽  
Vol 21 (2) ◽  
pp. 321-338 ◽  
Author(s):  
OLEG N. AGEEV
Keyword(s):  
Continuous Spectrum ◽  
Lebesgue Space ◽  
Unitary Operator ◽  
Multiplicity Function ◽  
Group Extensions ◽  
Geometric Models ◽  
Generic Group ◽  
Weakly Mixing ◽  
Generic Set

A modification of the method of geometric models is proposed and applied to the study of multiplicity functions of group extensions.It is proved that, for some generic set of the automorphisms T of the Lebesgue space with respect to the standard topology, for any M\subseteq {\mathbb N} \cup \{\infty\}(1\in M) there exists a generic set of weakly mixing group extensions T' of transformation T with M(T')=M, where M(T) denotes the set of essential spectral multiplicities of the unitary operator corresponding to the transformation T.

scholarly journals Other Types of Meaning: Relationships between Round Barrows and Landscapes from 1500 bc–ac 1086

2016 ◽  
Vol 26 (4) ◽  
pp. 665-696 ◽  
Author(s):  
Anwen Cooper
Keyword(s):  
Bronze Age ◽  
Extended Time ◽  
Generic Group ◽  
Time Period ◽  
Human Practices ◽  
Fresh Insight ◽  
Insight Into ◽  
Extended Time Period

This paper is about Bronze Age round barrows and the ways in which they became caught up in human practices over an extended time period. At one level it belongs to a flourishing body of work that examines the ‘re-use’ or ‘biography’ of prehistoric monuments. Rather than treating the latter as a generic group, however, this study focuses on chronologies of one specific monument type—round barrows—over a 2600-year period from 1500 bc–ac 1086. By bringing together evidence and interpretations generated mainly within period specialisms, significant homogeneities are revealed in terms of how activities at prehistoric monuments have previously been understood. The possibilities for seeking out different interpretative ground are duly explored. Using a case study from the east of England and drawing on evidence and ideas from much more broadly, the approach taken places particular emphasis on examining relationships between round barrows and other aspects of landscape. The findings offer fresh insight into the temporality of activities undertaken at round barrows, question existing characterizations of past people's historical understandings, and explore the long-term coherence of ‘round barrows’ as a category.

An Efficient Attribute-Based Signature with Application to Secure Attribute-Based Messaging System

2013 ◽  
pp. 159-177 ◽  
Author(s):  
Piyi Yang ◽  
Tanveer A Zia
Keyword(s):  
Standard Model ◽  
Secure Communications ◽  
Group Model ◽  
Challenging Problem ◽  
Anonymous Authentication ◽  
Generic Group ◽  
Model Based ◽  
The Standard Model ◽  
Single String ◽  
Generic Group Model

A set of attributes instead of a single string to represent the signer’s identity is a challenging problem under standard cryptographic assumption in the standard model. Therefore, designing a fully secure (adaptive-predicate unforgeable and perfectly private) Attribute-Based Signature (ABS) that allows a signer to choose a set of attributes is vital. Existing schemes are either too complicated or have only been proved in the generic group model. In this chapter, the authors present an efficient fully secure ABS scheme in the standard model based on q-parallel BDHE assumption, which is more practical than the generic group model used in the previous schemes. The proposed scheme is highly expressive since it allows any signer to specify claim-predicates in terms of any predicate consisting of AND, OR, and Threshold gates over the attributes in the system. ABS has found many important applications in secure communications, such as anonymous authentication systems and attribute-based messaging systems.

On the taxonomy of the genera Stigmatophora Staudinger, 1881 and Miltochrista Hübner, [1819], with description of a new species from North Thailand and China (Lepidoptera, Erebidae, Arctiinae, Lithosiini)

Zootaxa ◽  
2020 ◽  
Vol 4789 (2) ◽  
pp. 508-522
Author(s):  
ANTON V. VOLYNKIN
Keyword(s):  
New Species ◽  
Type Species ◽  
Southwest China ◽  
Species Level ◽  
Type Locality ◽  
New Combination ◽  
Generic Group ◽  
Previously Treated ◽  
North Thailand ◽  
A New Species

The generic group names Cymella Felder, 1874 and Myclela Watson, Fletcher & Nye, 1980 are excluded from the subtribe Nudariina and synonymized with the nominate subgenus of the genus Stigmatophora Staudinger, 1881 belonging to the subtribe Endrosiina. The type species of Cymella and Myclela, Cymella congerens Felder, 1874 is synonymized with the nominate subspecies of Stigmatophora (Stigmatophora) rhodophila (Walker, [1865]). The type locality of Cymella congerens is designated as Shanghai (E China). Two taxa previously treated as synonyms of S. congerens are upgraded to the species level and left in the genus Miltochrista Hübner, [1819]: Miltochrista artocarpi (Moore, 1878), stat. nov. and Miltochrista roseogrisea (Rothschild, 1913), stat. nov. The genus Asuropsis Matsumura, 1927 is excluded from the synonymy of Miltochrista and synonymized with the nominate subgenus of the genus Stigmatophora. The new combination is established: Stigmatophora (Stigmatophora) ranruna (Matsumura, 1927), comb. nov. A new species, Stigmatophora (Stigmatophora) cernyi Volynkin, sp. n. is described from North Thailand and Southwest China. Adults of both sexes of all the species mentioned and their genitalia are illustrated. 

Sign in / Sign up

Export Citation Format

Share Document